TWI888599B - 取代哌啶化合物及其用途 - Google Patents
取代哌啶化合物及其用途 Download PDFInfo
- Publication number
- TWI888599B TWI888599B TW110126031A TW110126031A TWI888599B TW I888599 B TWI888599 B TW I888599B TW 110126031 A TW110126031 A TW 110126031A TW 110126031 A TW110126031 A TW 110126031A TW I888599 B TWI888599 B TW I888599B
- Authority
- TW
- Taiwan
- Prior art keywords
- compound
- mmol
- azabicyclo
- added
- solution
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020122864 | 2020-07-17 | ||
| JP2020-122864 | 2020-07-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202216705A TW202216705A (zh) | 2022-05-01 |
| TWI888599B true TWI888599B (zh) | 2025-07-01 |
Family
ID=79291962
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110126031A TWI888599B (zh) | 2020-07-17 | 2021-07-15 | 取代哌啶化合物及其用途 |
| TW114120483A TWI922338B (zh) | 2020-07-17 | 2021-07-15 | 取代哌啶化合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW114120483A TWI922338B (zh) | 2020-07-17 | 2021-07-15 | 取代哌啶化合物及其用途 |
Country Status (32)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7833486B2 (ja) | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| JP7591592B2 (ja) * | 2022-01-14 | 2024-11-28 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物を含有する医薬 |
| WO2023136279A1 (ja) * | 2022-01-14 | 2023-07-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 置換ピペリジン化合物の結晶並びに置換ピペリジン化合物の塩及びそれらの結晶 |
| EP4600242A1 (en) * | 2022-10-07 | 2025-08-13 | Kissei Pharmaceutical Co., Ltd. | Cyclopentane compound |
| TW202432109A (zh) * | 2022-10-31 | 2024-08-16 | 日商武田藥品工業股份有限公司 | 食慾素２型受體促效劑之給藥 |
| JPWO2024128305A1 (cg-RX-API-DMAC10.html) | 2022-12-16 | 2024-06-20 | ||
| TW202502342A (zh) | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025137359A1 (en) | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008517032A (ja) * | 2004-10-20 | 2008-05-22 | ノイロサーチ アクティーゼルスカブ | 新規なジアザ二環式アリール誘導体及びその医薬用途 |
| JP4765627B2 (ja) * | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| JP2016512536A (ja) * | 2013-03-13 | 2016-04-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換した７−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG34208A1 (en) | 1995-03-01 | 1996-12-06 | Guy Andrew Vaz | Blast and fragment resistant polyurethane boot sole for safety footwear |
| EP0828751A4 (en) | 1995-05-05 | 1999-01-20 | Human Genome Sciences Inc | HUMAN NEUROPEPTIDE RECEPTOR |
| US6309854B1 (en) | 1996-12-17 | 2001-10-30 | Smithkline Beecham Corporation | Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72 |
| US6159605A (en) | 1997-02-18 | 2000-12-12 | Dainichiseika Color & Chemicals Mfg. Co., Ltd. | Ink-jet recording sheet |
| US5935814A (en) | 1997-04-30 | 1999-08-10 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72Y receptor |
| US6020157A (en) | 1997-04-30 | 2000-02-01 | Smithkline Beecham Corporation | Polynucleotides encoding HFGAN72X receptor |
| US6166193A (en) | 1997-07-25 | 2000-12-26 | Board Of Regents, University Of Texas System | Polynucleotides encoding MY1 receptor |
| KR100327888B1 (ko) | 1999-07-14 | 2002-03-09 | 정숭렬 | 도로포장 파손촉진 시험장치의 무선제어 시스템 |
| JP2009184924A (ja) | 2006-05-31 | 2009-08-20 | Eisai R & D Management Co Ltd | 生物学的試薬用化合物 |
-
2021
- 2021-07-15 CN CN202411459551.4A patent/CN119235864A/zh active Pending
- 2021-07-15 HR HRP20260428TT patent/HRP20260428T1/hr unknown
- 2021-07-15 BR BR112022026161A patent/BR112022026161A2/pt unknown
- 2021-07-15 US US17/376,452 patent/US11479552B2/en active Active
- 2021-07-15 FI FIEP21842047.9T patent/FI4151277T3/fi active
- 2021-07-15 PH PH1/2022/553488A patent/PH12022553488A1/en unknown
- 2021-07-15 UA UAA202204882A patent/UA129636C2/uk unknown
- 2021-07-15 AU AU2021308053A patent/AU2021308053A1/en active Pending
- 2021-07-15 DK DK21842047.9T patent/DK4151277T3/da active
- 2021-07-15 TW TW110126031A patent/TWI888599B/zh active
- 2021-07-15 LT LTEPPCT/JP2021/026649T patent/LT4151277T/lt unknown
- 2021-07-15 AR ARP210101982A patent/AR122973A1/es unknown
- 2021-07-15 PT PT218420479T patent/PT4151277T/pt unknown
- 2021-07-15 MX MX2022016388A patent/MX2022016388A/es unknown
- 2021-07-15 RS RS20260400A patent/RS67943B1/sr unknown
- 2021-07-15 CN CN202411462171.6A patent/CN119258067A/zh active Pending
- 2021-07-15 ES ES21842047T patent/ES3067008T3/es active Active
- 2021-07-15 CN CN202180044081.3A patent/CN115884971B/zh active Active
- 2021-07-15 SI SI202130423T patent/SI4151277T1/sl unknown
- 2021-07-15 KR KR1020227044679A patent/KR20230040953A/ko active Pending
- 2021-07-15 MA MA59554A patent/MA59554B1/fr unknown
- 2021-07-15 TW TW114120483A patent/TWI922338B/zh active
- 2021-07-15 WO PCT/JP2021/026649 patent/WO2022014680A1/ja not_active Ceased
- 2021-07-15 PE PE2022003006A patent/PE20231103A1/es unknown
- 2021-07-15 SM SM20260159T patent/SMT202600159T1/it unknown
- 2021-07-15 CA CA3187835A patent/CA3187835A1/en active Pending
- 2021-07-15 IL IL299125A patent/IL299125B2/en unknown
- 2021-07-15 MD MDE20230329T patent/MD4151277T2/ro unknown
- 2021-07-15 JP JP2022536446A patent/JP7190612B2/ja active Active
- 2021-07-15 EP EP21842047.9A patent/EP4151277B1/en active Active
- 2021-07-15 PL PL21842047.9T patent/PL4151277T3/pl unknown
-
2022
- 2022-12-14 ZA ZA2022/13562A patent/ZA202213562B/en unknown
- 2022-12-20 CL CL2022003666A patent/CL2022003666A1/es unknown
- 2022-12-20 CO CONC2022/0018446A patent/CO2022018446A2/es unknown
- 2022-12-21 JO JOJO/P/2022/0345A patent/JOP20220345A1/ar unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4765627B2 (ja) * | 2003-09-22 | 2011-09-07 | Ｍｓｄ株式会社 | 新規ピペリジン誘導体 |
| JP2008517032A (ja) * | 2004-10-20 | 2008-05-22 | ノイロサーチ アクティーゼルスカブ | 新規なジアザ二環式アリール誘導体及びその医薬用途 |
| JP2016512536A (ja) * | 2013-03-13 | 2016-04-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換した７−アザビシクル及びオレキシン受容体調節因子としてのそれらの使用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI922338B (zh) | 取代哌啶化合物及其用途 | |
| TW201018663A (en) | Fluorene compound and pharmaceutical use thereof | |
| JP6533799B2 (ja) | 放射標識された化合物 | |
| CN103492370B (zh) | 取代的二氨基甲酰胺和二氨基甲腈嘧啶，其组合物，和用其治疗的方法 | |
| JP2024517678A (ja) | ソルチリン活性の修飾物質 | |
| TW202340145A (zh) | 氘化有機化合物及其用途 | |
| US12606523B2 (en) | Deuterated organic compounds and uses thereof | |
| KR101800140B1 (ko) | 벤조티아졸론 화합물 | |
| TW202432509A (zh) | 對於食慾素-2受體拮抗劑之製備有用之方法及化合物、以及雜質少之萊博雷生 | |
| KR20220106778A (ko) | 간 x 수용체 작용제로서의 1,2,4-옥사디아졸 유도체 | |
| EP4438602A1 (en) | Crystal of substituted piperidine compound, salts of substituted piperidine compound, and crystals thereof | |
| JP7591592B2 (ja) | 置換ピペリジン化合物を含有する医薬 | |
| RU2840772C1 (ru) | Замещенные пиперидиновые соединения и их применение | |
| EA045865B1 (ru) | Замещенные пиперидиновые соединения и их применение | |
| HK40083601B (en) | Substituted piperidine compound and application thereof | |
| HK40083601A (en) | Substituted piperidine compound and application thereof |